Please wait a minute...
Shopping Cart Email List Chinese
Advanced Search Fig/Tab
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Featured Articles  |  Most Downloaded  |  Most Reading
Online Submission Subscribe to Our RSS Content Feed
Front Med    0, Vol. Issue () : 127-133    https://doi.org/10.1007/s11684-011-0137-7
REVIEW
Developments in cancer prevention and treatment using traditional Chinese medicine
Hongsheng Lin(), Jie Liu, Ying Zhang
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
 Download: PDF(115 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

Through the joint efforts of several generations of practitioners in traditional Chinese medicine (TCM) and integrated medicine of oncology, we have made some achievements in cancer treatment using TCM in over 50 years, including treatment concepts, methods, and basic and clinical research. Currently, TCM plays an indispensable role in cancer prevention and treatment. However, we also clearly recognize that there are some issues that have yet to be resolved. In the future, cancer treated with TCM will face unprecedented opportunities and challenges. This article reviews the developments of TCM in the treatment of cancer.
Keywords traditional Chinese medicine (TCM)      cancer     
Corresponding Author(s): Lin Hongsheng,Email:drlinhongsheng@163.com   
Issue Date: 05 June 2011
 Cite this article:   
Hongsheng Lin,Jie Liu,Ying Zhang. Developments in cancer prevention and treatment using traditional Chinese medicine[J]. Front Med, 0, (): 127-133.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-011-0137-7
https://academic.hep.com.cn/fmd/EN/Y0/V/I/127
StageKey principlesMain purposes
PrecancerousEliminate the evil factorsPrevent tumorigenesis
Cancer initial treatmentPresurgery: strengthen the body resistanceEnhance the efficacy and reduce the toxicity of conventional treatments
After-surgery: nourish Qi, promote blood circulation, detoxify
During chemotherapy: reinforce the spleen and kidneys as well as tonify the blood and Qi
During radiotherapy: nourish Qi and Yin, activate blood, and detoxify
Tumor remission or stabilizationStrengthen body resistance and eliminate the evil factorsPrevent recurrence or metastasis and disease progression, and prolong survival
Without indications of conventional treatments or End stageGood performance status: eliminate the evil factors (Quxie) and support vital Qi (Fuzheng) as supplementImprove QOL and prolong survival
Moderate performance status: Give equal stress to Fuzheng and Quxie
Poor performance status: Fuzheng and Quxie as supplement
Tab.1  TCM treatment strategies for cancer patients
1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010. Available from: http://globocan.iarc.fr
2 Han YY, Feng P, Wen ZhY. Research development on Chinese herbs of anticancer. J Beijing TCM (Bei Jing Zhong Yi) 2003; (2):45–48 (in Chinese)
3 Gao WB. Research development on Chinese herbs of anticancer. Med J Liaoning (Liao Ning Yi Yao) 1977; (6): 29–33 (in Chinese)
4 Tian JZh. Pharmacological classification and clinical significance of anti-cancer Chinese herbs. J Shandong College Tradit Chin Med (Shan Dong Zhong Yi Xue Yuan Xue Bao) 1986; 10(2): 16–19 (in Chinese)
5 Tang MX, Yu GQ, Duan FW. An antitumorigenic study by a TCM formula belonging to the category of enhancing the righteousness and consolidating the foundation. Chin J Cancer (Ai Zheng) 1986; 5(1): 65–69 (in Chinese)
6 Zhang DZh, Xu JD, Li PW, Dong XR, Hao YX, Li X, Cai GR, Cui HJ, Wan DG, Zhou W, Yu GQ. Clinical and experimental researches on improving radiation sensibility for lung cancer patients by “Fu Zheng Zeng Xiao”(FZ). Chin J Surg of Integr Tradit West Med (Zhongguo Zhong Xi Yi Jie He Wai Ke Za Zhi) 1998; 4(2): 71–75 (in Chinese)
7 Liu JX, Xu ZY, Shi ZM, Guo YH, Fan ZhZ, Li MH, Huang JM, Zhu YW, Zhao LH, Shi ChM, Gao H, Chen SX. Prospective study on Fuzheng treatment in 122 advanced non-small cell lung cancer patients. China J Tradit Chin Med Pharm(Zhongguo Yi Yao Xue Bao) 1987; 2(1): 12–16 (in Chinese)
8 Pan MJ, Li YH, Chen LF. Observation of the long term curative effect of 150 cases of nasopharyngeal cancer treated with Fu Zheng Sheng Jin decoction and radiotherapy. J Integr Tradit West Med(Zhong Xi Yi Jie He Za Zhi) 1985; 5(2): 83–85 (in Chinese)
9 Cai WM, Hu YH, Zhang HX, Xu GZh, Qin DX, Wu XL, Yan JH, Gu XZh. Prospective controlled trial of nasopharyngeal carcinoma treated with traditional Chinese medicine and radiation therapy. J Tradit Chin Med (Zhong Yi Za Zhi) 1983; (9): 36–38 (in Chinese)
10 Zhang DZh. Integrated traditional Chinese medicine and western medicine in advanced lung cancer. J China-Japan Friendship Hosp(Zhong Ri You Hao Yi Yuan Xue Bao) 1987; 1(1): 33–37 (in Chinese)
11 Liu LM, Lin ShY, Wu LC, Wang ZS, Zhou WSh, Guo Y, Shen MH, Yang WH. Xie ChSh. Clinical observation on the synergic and detoxified action of injection of Radix Codonopsis and Radix Ophiopogonis in chemotherapy of lung cancer. J Tradit Chin Med (Zhong Yi Za Zhi)1994; 35(5): 280–282 (in Chinese)
12 Sun GZh, Wang GM, Chen ChH, Song L, Zhang PT, Pan XM, Hou W, Zhang PY, Yang ZY. YGQ. Clinical and experimental study on treatment of advanced gastrointestinal carcinoma with FuzhengFangai oral liquid combined with chemotherapy. Chin J Surg of Integr Tradit West Med (Zhonguo Zhong Xi Yi Jie He Wai Ke Za Zhi)1995; 1(5): 266–270 (in Chinese)
13 Fang XX, Wang ShH, Li LQ, Wang L. Observation of treatment with integrative medicine to reduce chemotherapy-induced leukocyte and platelet in 168 patients. J Clin Oncol (Lin Chuang Zhong Liu Xue Za Zhi) 1997; 2(3): 56 (in Chinese)
14 Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, Yi Z, Liu M. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010; 31(12): 2097–2104
doi: 10.1093/carcin/bgq167 pmid:20732905
15 Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328(5975): 240–243
doi: 10.1126/science.1183424 pmid:20378816
16 Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68(11): 4347–4351
doi: 10.1158/0008-5472.CAN-07-2970 pmid:18519695
17 Chen X, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 2005; 106(7): 2409–2416
doi: 10.1182/blood-2005-03-0854 pmid:15956285
18 Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, Hsieh SC, Hsiao PW. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 2009; 15(17): 5435–5444
doi: 10.1158/1078-0432.CCR-09-0298 pmid:19690196
19 Lin HS, Li ShQ, Piao BK. Effective evaluation methods for treatment with traditional Chinese medicine in advanced lung cancer. Bull Chin Cancer (Zhongguo Zhong Liu) 2000; 9(8): 354–355 (in Chinese)
20 Zhang PT, Yu MW, Yang ZY, Li DR, Liu YH, Lin HSh. Compared study on effective evaluation methods of TCM and WM in advanced non-small cell lung cancer. J Integr Tradit West Med (Zhong Xi Yi Jie He Za Zhi) 2010; 30(7): 702–705 (in Chinese)
21 Lin LZh, Lan ShQ, Zhou DH. A discussion on the criterion of therapeutical effect of malignant tumor(solid carcinoma) in TCM. New J Tradit Chin Med (Xin Zhong Yi) 2001; 33(8): 5–6 (in Chinese)
22 Sun HY, Xing YM, Li YW, Liu DY, Xie GR. Quality evaluation of randomized controlled trails in Chinese medicine combined with chemotherapy in non-small cell lung cancer. 3rd International Congress of TCM and Integrated TCM-WM Oncology. 2010, 84–85 (in Chinese)
23 Lin HSh, Zhang Y. Evidence-based medical study of TCM on non-small cell lung cancer. World Sci Technol—Modernization Tradit Chin Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2008;(4): 121–125 (in Chinese)
24 Sun Y, Lin H, Zhu YZH, Feng JF, Chen ZhT, Li GS, Zhang XR, Zhang ZQ, Tang JF, Shi MQ, Hao XZH, Han H. A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Zhongguo Fei Ai Za Zhi) 2006; 9(3): 254–258 (in Chinese)
25 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer V.2. 2009.Available from: http://www.nccn.org.
26 Zheng ChS, Chen LW, Huang Q, Hu J, Du J, Xu XJ. Establishment of computer simulation analysis for Multi-target anti-tumor effect of Chinese medicine. J Fujian College Tradit Chin Med (Fu Jian Zhong Yi Xue Yuan Xue Bao) 2007; 17(3): 37–40 (in Chinese)
27 Wu Q, Bi ZhM, Li P, Qi LW. Advances in biological screening-chemical analysis of the bioactive components in traditional Chinese medicines based on holistic characteristics. J China Pharm Univ (Zhongguo Yao Ke Da Xue Xue Bao) 2007; 38(4): 289–293 (in Chinese)
28 Hao H, Cui N, Wang G, Xiang B, Liang Y, Xu X, Zhang H, Yang J, Zheng C, Wu L, Gong P, Wang W. Global detection and identification of non-target components from herbal preparations by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a strategy. Anal Chem 2008; 80(21): 8187–8194
doi: 10.1021/ac801356s pmid:18795791
29 Zhou XZh, Liu BY, Yao NL, Chen SB, Li P,Wang YH,Zhang RSh. Studies and Applications: TCM Clinical Data Warehouse and Associated Data Mining Platform. World Sci Technol—Modernization Tradit Chin Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2007; 9(4): 74–80 (in Chinese)
30 Liu J, Lin HSh, Hou W, Li DR, Zhou XZh. Pilot study on the characteristics of Chinese medicine treatment in lung cancer patients by use of data mining methods. World Sci Technol—Modernization Tradit Chin Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2009; 11(5): 753–757 (in Chinese)
31 Investment Advisor in the Industry Research Center. 2010–2015 Investment Analysis of Chinese medicine industry and Forecast Report. 2010,5. Available from: http://www.con.com.cn
32 Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22(12): 2489–2503
doi: 10.1200/JCO.2004.08.182 pmid:15197212
33 Gan T, Wu Z, Tian L, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev 2010; (1): CD005096
pmid:20091570
34 Wei X, Chen Z, Yang X, Wu T. Chinese herbal medicines for esophageal cancer. Cochrane Database Syst Rev 2009; (4): CD004520
pmid:19821327
35 McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006; 24(3): 419–430
doi: 10.1200/JCO.2005.03.6392 pmid:16421421
[1] Tianzhuo Wang, Huiying Guo, Lei Zhang, Miao Yu, Qianchen Li, Jing Zhang, Yan Tang, Hongquan Zhang, Jun Zhan. FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression[J]. Front. Med., 2023, 17(4): 714-728.
[2] Ying Dong, Yingbei Qi, Haowen Jiang, Tian Mi, Yunkai Zhang, Chang Peng, Wanchen Li, Yongmei Zhang, Yubo Zhou, Yi Zang, Jia Li. The development and benefits of metformin in various diseases[J]. Front. Med., 2023, 17(3): 388-431.
[3] Mingyue Tan, Qi Pan, Qi Wu, Jianfa Li, Jun Wang. Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2[J]. Front. Med., 2023, 17(3): 503-517.
[4] Xueqing Hu, Ujjwol Khatri, Tao Shen, Jie Wu. Progress and challenges in RET-targeted cancer therapy[J]. Front. Med., 2023, 17(2): 207-219.
[5] Yifan Chang, Xianzhi Zhao, Yutian Xiao, Shi Yan, Weidong Xu, Ye Wang, Huojun Zhang, Shancheng Ren. Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial[J]. Front. Med., 2023, 17(2): 231-239.
[6] Danhui Weng, Huihua Xiong, Changkun Zhu, Xiaoyun Wan, Yaxia Chen, Xinyu Wang, Youzhong Zhang, Jie Jiang, Xi Zhang, Qinglei Gao, Gang Chen, Hui Xing, Changyu Wang, Kezhen Li, Yaheng Chen, Yuyan Mao, Dongxiao Hu, Zimin Pan, Qingqin Chen, Baoxia Cui, Kun Song, Cunjian Yi, Guangcai Peng, Xiaobing Han, Ruifang An, Liangsheng Fan, Wei Wang, Tingchuan Xiong, Yile Chen, Zhenzi Tang, Lin Li, Xingsheng Yang, Xiaodong Cheng, Weiguo Lu, Hui Wang, Beihua Kong, Xing Xie, Ding Ma. Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial[J]. Front. Med., 2023, 17(1): 93-104.
[7] Jia Zhong, Hua Bai, Zhijie Wang, Jianchun Duan, Wei Zhuang, Di Wang, Rui Wan, Jiachen Xu, Kailun Fei, Zixiao Ma, Xue Zhang, Jie Wang. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions[J]. Front. Med., 2023, 17(1): 18-42.
[8] Shi-Yong Sun. Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors[J]. Front. Med., 2022, 16(5): 701-713.
[9] Jianhua Shi, Ying Cheng, Qiming Wang, Kai Li, Lin Wu, Baohui Han, Gongyan Chen, Jianxing He, Jie Wang, Haifeng Qin, Xiaoling Li. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)[J]. Front. Med., 2022, 16(5): 766-772.
[10] Xiang Wang, Minghui Wang, Lin Feng, Jie Song, Xin Dong, Ting Xiao, Shujun Cheng. Four-protein model for predicting prognostic risk of lung cancer[J]. Front. Med., 2022, 16(4): 618-626.
[11] Yaru Tian, Hairong Tian, Xiaoyang Zhai, Hui Zhu, Jinming Yu. Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis[J]. Front. Med., 2022, 16(4): 610-617.
[12] Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani, Fatemeh Rahbarizadeh. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?[J]. Front. Med., 2022, 16(3): 322-338.
[13] Ying Deng, Zhaowei Sun, Lei Wang, Minghui Wang, Jie Yang, Genxi Li. Biosensor-based assay of exosome biomarker for early diagnosis of cancer[J]. Front. Med., 2022, 16(2): 157-175.
[14] Qiaoli Shi, Fei Xia, Qixin Wang, Fulong Liao, Qiuyan Guo, Chengchao Xu, Jigang Wang. Discovery and repurposing of artemisinin[J]. Front. Med., 2022, 16(1): 1-9.
[15] Wenjing Zhou, Jing Zhang, Mingkun Yan, Jin Wu, Shuo Lian, Kang Sun, Baiqing Li, Jia Ma, Jun Xia, Chaoqun Lian. Orlistat induces ferroptosis-like cell death of lung cancer cells[J]. Front. Med., 2021, 15(6): 922-932.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed